ArticleInternational journal of surgery (London, England)2025

SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study.

Jingjun Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.